Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

The impact of nighttime lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) such as nocturia has long been underestimated. Lack of sleep because of these symptoms can considerably affect a patient's performance and his general feeling of well-being. Chronic sleep deficit may lead to increased morbidity and mortality. Therefore, it is important that therapies for LUTS/BPH provide a proper control of nighttime LUTS. Numerous studies in the field of sleep disorders have shown that increasing the length and quality of sleep (QoS) can result in a significant improvement in energy and quality of life (QoL). To relieve nocturnal symptoms of BPH and to improve patients’ QoS and QoL, a new prolonged-release tablet formulation of the α1-adrenoceptor antagonist tamsulosin using the Oral Controlled Absorption System (OCAS) technology was recently developed. Tamsulosin is slowly released from the OCAS tablet throughout the entire gastrointestinal tract, including the colon, and thus provides a relatively stable 24-h plasma concentration of tamsulosin. Due to its advanced delivery system, tamsulosin OCAS is expected to relieve nighttime symptoms of LUTS/BPH and to improve QoS and QoL.